TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04707209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: An intravitreal injection of 20 µL of drug will be given through the pars plana of the eye. The injected eye will be treated with topical antibiotic and steroid eye drops prescribed for 7 to 10 days after the injection. The first injection will only be provided into the worse eye despite both eyes showing signs of exudation. Injection into the other eye will be considered only two months after the safety of this first injection is determined.~Safety and efficacy of treatment will be determined by repeat eye examinations in the eye clinic one day, one week and one month after each injection.~The interval between injections is roughly suggested to be between 3 to 8 weeks based on the drug deposit present in the eye. A total of 3-12 injections will be given per eye, over 6-24 months.
Study: NCT02704884

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic soy milk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic soy milk
Study: NCT00668642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: 0.5 mg capsule given orally on daily basis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo
Study: NCT02469740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 90 mg BD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 90 mg BD orally for 5 weeks (4 weeks plus a 1 week washout period).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 75 mg OD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 75 mg OD orally for 5 weeks (4 weeks plus a 1 week washout period).
Study: NCT03320317

Intervention type: OTHER
Intervention: Learning session 1
Description: Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures

Intervention type: OTHER
Intervention: Learning session 2
Description: Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis

Intervention type: OTHER
Intervention: Learning session 3
Description: Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures

Intervention type: OTHER
Intervention: Learning session 4
Description: Feedback report, Best practice symposium
Study: NCT02646514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation with stenting
Description: Side viewing endoscope or PTCS scope can be used for all procedures. Cholangiogram is performed to confirm the stricture location, length and diameter. And then, RF catheter (ELRA®) is advanced over a guide wire at the level of the biliary stricture and ablation at 7-10 watts for a time period of 60-120s according to the length is conducted.~After performance of RFA, metal stents are inserted to ensure adequate decompression and bile drainage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenting
Description: Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
Study: NCT01871142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 100 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aes-103
Description: Single dose of 1000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aes-103
Description: Single dose of 3000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
Study: NCT04300231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural bupivacaine 0.05%
Description: Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 20 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 20 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.125%
Description: 40 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.125%
Description: 40 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 0.5%
Description: 60 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: /hydromorphone 0.05mg/ml
Description: Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injectable saline
Description: 40 mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injectable saline
Description: 40 mL
Study: NCT03334149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-Monitoring of Blood Pressure
Description: BUMP 1: Women randomised to the self-monitoring arm will be asked to measure blood pressures at least three times a week. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, and aided by the tele monitoring system.~BUMP 2: Women randomised to the self-monitoring arm will be asked to measure blood pressures daily. They will perform two readings with a one minute interval and will be asked to act on the second reading if it falls outside their normal range thresholds described in their instructions, aided by a tele monitoring system.
Study: NCT03895619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safer conception strategies
Description: Individuals and couples adopt safer conception strategies including HIV-serostatus disclosure to partner, ART uptake and adherence and HIV-RNA suppression, STI testing and treatment, timing condomless sex to peak fertility, partner ARV use (ART if living with HIV, PrEP if HIV negative), and contraception until ready to conceive.
Study: NCT04300231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injectable saline
Description: 40 mL
Study: NCT04576325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole Inhalation Powder
Description: For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules for a given dose must be inhaled over a maximum 10-minute period. Cohort 1 will receive 40 mg BID and Cohort 2 will receive 80 mg BID. Both Cohorts will administer study drug for 3.5 days (7 days total).
Study: NCT04072315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809
Study: NCT04133363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation using L-PRF/FDBA layered technique
Description: Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA layered technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation using L-PRF/FDBA
Description: Atraumatic tooth extraction following by socket grafting using L-PRF/FDBA
Study: NCT04576325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For each dose, multiple inhalations will be required (4 capsules in Cohort 1 and 8 capsules in Cohort 2). All capsules must be inhaled over a maximum 10-minute period. Cohort 1 will receive 4 capsules of inactive BID and Cohort 2 will receive 8 capsules of inactive BID. Both Cohorts will administer placebo capsules for 3.5 days (7 days total).
Study: NCT01409434

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Glucose Tolerance Test
Description: Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
Study: NCT04133363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge preservation using L-PRF
Description: Atraumatic tooth extraction following by socket grafting using L-PRF
Study: NCT04045470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdevices
Description: The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microdevices
Description: The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care therapy
Description: Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy
Study: NCT03179527

Intervention type: DRUG
Group type: OTHER
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Platelet Drugs
Description: Including aspirin and clopidogrel, etc

Intervention type: DRUG
Group type: OTHER
Intervention: Lipid Regulating Drugs
Description: Mainly including statins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid Regulating Drugs
Description: Mainly including statins

Intervention type: DRUG
Group type: OTHER
Intervention: Coronary Vasodilator
Description: Mainly including nitrates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coronary Vasodilator
Description: Mainly including nitrates

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuanghe Decoction
Description: Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
Study: NCT04045470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care systemic therapy
Description: Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which must include a systemic therapy.
Study: NCT01939158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: 1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: 1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
Study: NCT05012579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cala Device
Description: transcutaneous afferent patterned stimulation (TAPS)
Study: NCT03290521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraperitoneal washing with saline solution
Description: intraperitoneal washing at the end of surgery
Study: NCT01939158

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: 1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine GSK134612
Description: 1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13™
Description: 1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
Study: NCT04072315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLN-74809
Description: PLN-74809

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Knottin tracer
Description: Radiotracer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Knottin tracer
Description: Radiotracer
Study: NCT01939158

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13™
Description: 1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
Study: NCT04072315

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Knottin tracer
Description: Radiotracer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Knottin tracer
Description: Radiotracer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Knottin tracer
Description: Radiotracer
Study: NCT02218255

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eeva™ results

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eeva™ results
Study: NCT02272699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 200mg per week for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 200mg per week for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: IMRT of primary tumor and local lymph nodes with 95% PTV of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Esophagectomy
Study: NCT04310046

Intervention type: PROCEDURE
Group type: OTHER
Intervention: PCI before TAVI
Description: TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
Study: NCT02272699

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Esophagectomy
Study: NCT05427357

Intervention type: OTHER
Group type: OTHER
Intervention: Non-selective closed kinetic chain exercises (NSKCE) and selective closed kinetic chain exercises (SCKCE)
Description: Non-selective closed kinetic chain double-leg semi-squat exercise In this exercise, the standing patient leans his or her back against the wall and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats. The knee stayed at flexion position for 10 seconds in each repeat, which aimed the contraction of quadriceps muscle. There is a relaxation period for 5 seconds between each repeat.~Selective closed kinetic chain double-leg semi-squat exercise with hip adduction In this exercise, the standing patient leans his or her back against the wall, forces the knees for adduction by squeezing the pillow placed between the knees and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-selective closed kinetic chain exercises (NSKCE) and selective closed kinetic chain exercises (SCKCE)
Description: Non-selective closed kinetic chain double-leg semi-squat exercise In this exercise, the standing patient leans his or her back against the wall and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats. The knee stayed at flexion position for 10 seconds in each repeat, which aimed the contraction of quadriceps muscle. There is a relaxation period for 5 seconds between each repeat.~Selective closed kinetic chain double-leg semi-squat exercise with hip adduction In this exercise, the standing patient leans his or her back against the wall, forces the knees for adduction by squeezing the pillow placed between the knees and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-selective closed kinetic chain exercises (NSKCE) and selective closed kinetic chain exercises (SCKCE)
Description: Non-selective closed kinetic chain double-leg semi-squat exercise In this exercise, the standing patient leans his or her back against the wall and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats. The knee stayed at flexion position for 10 seconds in each repeat, which aimed the contraction of quadriceps muscle. There is a relaxation period for 5 seconds between each repeat.~Selective closed kinetic chain double-leg semi-squat exercise with hip adduction In this exercise, the standing patient leans his or her back against the wall, forces the knees for adduction by squeezing the pillow placed between the knees and slides down the wall until the knees are about 45 degrees flexed. Daily program was determined as 5 sessions and 10 repeats.
Study: NCT02721511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection Solution 8mg/mL
Description: Furosemide Injection Solution, 8 mg/mL, (total dose =80 mg) administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours by means of the B. Braun Perfusor® Space Infusion Pump System.
Study: NCT03573362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViziShot FLEX 19G needle
Description: EBUS-TBNA using the ViziShot FLEX 19G needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vizishot 22G needle (standard)
Description: EBUS-TBNA using the Vizishot 22G needle (standard)
Study: NCT00944684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High ribavirin dose
Description: Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
Study: NCT03299387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin
Description: Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
Study: NCT04310046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI after TAVI
Description: TAVI is performed using the Edwards SAPIEN Transcatheter Heart Valve®. PCI is performed in any suitable lesion with ≥70% diameter stenosis on coronary angiography in a coronary artery ≥2.5 mm in diameter.
Study: NCT01137396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil 400mg PO QDaily following up-titration for \~8weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Once weekly cognitive behavioral therapy for cocaine dependence
Study: NCT03060187

Intervention type: OTHER
Intervention: KU Score
Description: Exam with a max score of 10 and min score of 0. Designed as a preoperative assessment of the patient's airway.
Study: NCT00521716

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracapsular Femoral Fracture Fixation
Description: The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WaisFix100i for Intracapsular Femoral Fracture Fixation
Description: The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
Study: NCT03392662

Intervention type: DEVICE
Intervention: Hemopatch
Description: Patients received product at the discretion of their surgeon.

Intervention type: DEVICE
Intervention: Hemopatch
Description: Patients received product at the discretion of their surgeon.

Intervention type: DEVICE
Intervention: Hemopatch
Description: Patients received product at the discretion of their surgeon.

Intervention type: DEVICE
Intervention: Hemopatch
Description: Patients received product at the discretion of their surgeon.
Study: NCT01137396

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Once weekly cognitive behavioral therapy for cocaine dependence
Study: NCT03392662

Intervention type: DEVICE
Intervention: Hemopatch
Description: Patients received product at the discretion of their surgeon.

Intervention type: DEVICE
Intervention: Hemopatch
Description: Patients received product at the discretion of their surgeon.
Study: NCT00944684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard ribavirin dose
Description: Ribavirin dose started at 1,000mg (body weight \<65kg) or 1,200mg (body weight equal or \>65kg)
Study: NCT00927251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing Lead (Model 4296 LV Lead)
Description: Implant and follow-up of study device
Study: NCT03847363

Intervention type: PROCEDURE
Intervention: epidural anesthesia
Description: epidural anesthesia

Intervention type: PROCEDURE
Intervention: nerve block
Description: paravertebral or serratus anterior plane block
Study: NCT02913131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyruvate (13C)
Description: Pyruvate injection followed by an MRI scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyruvate (13C)
Description: Pyruvate injection followed by an MRI scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan following the pyruvate (13c) injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan following the pyruvate (13c) injection
Study: NCT05127135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART7 cells
Description: 0.5-6 x 10\^6 CAR T cells per kg body weight
Study: NCT00802919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline 1-2 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for varenicline
Description: Placebo
Study: NCT06081803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repatha®
Description: Repatha® 140mg x 3 pens subcutaneous injection
Study: NCT00942448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac HPBCD
Description: 1 single injection at day of dental surgical extraction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac HPBCD
Description: 1 single injection at day of dental surgical extraction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac HPBCD
Description: 1 single injection at day of dental surgical extraction

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo s.c.
Description: 1 single injection at day of dental surgical extraction
Study: NCT01278693

Intervention type: DRUG
Group type: OTHER
Intervention: L-carnitine
Description: 500 mg,twice daily, 16 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: 500 mg,twice daily, 16 weeks.